Aurobindo Pharma Forms Wholly Owned Subsidiary in France to Expand Generic Manufacturing
Aurobindo Pharma Limited has announced the incorporation of a new wholly owned subsidiary in France, marking an expansion of its global manufacturing footprint. The new entity is named Arrow Pharma Production SAS.The incorporation was finalized on May 21, 2026. Arrow Pharma Production SAS is established through Agile Pharma BV, the Netherlands. Agile Pharma BV operates as a wholly owned step-down subsidiary of Aurobindo Pharma Limited, making the newly incorporated French entity a wholly owned step-down subsidiary for the listed company.
The strategic objective of this new subsidiary is to expand the manufacturing capacity for generic formulations within the French market. The company confirmed that no governmental or regulatory approvals were required for this incorporation.
The establishment was structured as a cash subscription, with a total authorized capital of 100,000 EUR. Details regarding the ownership and capital structure are as follows:
| Detail | Description |
|---|---|
| New Entity | Arrow Pharma Production SAS (France) |
| Incorporation Date | May 21, 2026 |
| Industry | Pharmaceuticals (Generic Formulations) |
| Holding Company | Agile Pharma BV, the Netherlands |
| Nature of Consideration | 100% subscription to share capital in cash |
| Authorized Capital | 100,000 EUR |
| Shares Issued | 100,000 shares of 1 EUR each |
| Shareholding | 100% shareholding |
AUROPHARMA Stock Price Movement
As of 12:45 PM, shares of Aurobindo Pharma Limited are slipping by 5.99% in live trading, currently trading at ₹1,454.00. The stock is under selling pressure, with over 1.57 million shares traded in the session today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.